Brief: Mustang Bio Reports Updated Interim Data From Ongoing Clinical Trial Of MB-106
25/04/2022 13:10
April 25 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO INC - ANNOUNCED UPDATED INTERIM DATA FROM
ONGOING
PHASE 1/2 CLINICAL TRIAL OF MB-106
* MUSTANG BIO - VERY FAVORABLE SAFETY PROFILE SUITABLE FOR
OUTPATIENT TREATMENT, HIGH COMPLETE RESPONSE RATE AND STRONG
DURABILITY OBSERVED FOR MB-106
* MUSTANG BIO INC - EXPECT TO DOSE FIRST PATIENT IN
MULTICENTER
CLINICAL TRIAL THIS QUARTER FOR MB-106
Source text for Eikon: ID:nGNX9CgZkT
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie